Etigilimab (TIGIT/VSTM3) - Research Grade Biosimilar
Product Specifications
Background
Etigilimab is human-derived monoclonal antibody. Etigilimab targets TIGIT. It started clinical research for the treatment of advanced solid tumors in the United States in 2017 and is currently in clinical phase I.
Immunogen
Humanized / TIGIT/VSTM3 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Cancer, Immunology
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-885
Fragment
IgG1-kappa
NCBI Organism
Homo sapiens
Other Product Names
OMP-313M32
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items